IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
Relative valuation derived from Healthcare sector median benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Multiples adjusted for extreme outliers and non-recurring volatility.
Auditing capital efficiency...
Quality Profile Audit
Score: 33.2GRADE D
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation.
Return on Equity
Profit generated per dollar of shareholder equity
-7.0%
Sector: -43.5%
Dividend Analysis audit
No Dividend
This company does not currently pay a dividend.
Analyst Projections
Analyst Consensus
Unlock Valuation Tools
Sign up for free access to institutional-quality research tools.
Based on our 6-factor quantitative model, Quipt Home Medical Corp. (QIPT) receives a "Hold" rating with a composite score of 44.4/100, ranked #616 out of 4446 stocks. Key factor scores: Quality 33/100, Value 39/100, Momentum 65/100. This is quantitative analysis only — not investment advice.
Quipt Home Medical Corp. (QIPT) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Quipt Home Medical Corp. Do?
Quipt Home Medical Corp. provides in-home medical equipment and supplies, and respiratory and durable medical equipment in the United States. The company also offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. In addition, it provides nebulizers, oxygen concentrators, CPAP and BiPAP units, ventilator equipment and aids, daily and ambulatory aides, equipment solutions, power wheelchairs, oxygen therapy, bariatric equipment, bathroom safety products, bilevel positive airway pressure, canes/crutches, continuous positive airway pressure, CPAP masks and accessories, hospital beds, humidifiers, compressors, patient lifts, walkers, products for wound care, and medical equipment for home-based sleep apnea and chronic obstructive pulmonary disease treatments, as well as rents respiratory equipment. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. was incorporated in 1993 and is headquartered in Wilder, Kentucky. Quipt Home Medical Corp. (QIPT) is classified as a micro-cap stock in the Healthcare sector. The company is led by CEO Gregory J. Crawford and employs approximately 800 people. With a market capitalization of $162M, QIPT is one of the notable companies in the Healthcare sector.
Quipt Home Medical Corp. (QIPT) Stock Rating — Hold (April 2026)
As of April 2026, Quipt Home Medical Corp. receives a Hold rating with a composite score of 44.4/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.QIPT ranks #616 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Quipt Home Medical Corp. ranks #36 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
QIPT Stock Price and 52-Week Range
Quipt Home Medical Corp. (QIPT) currently trades at $3.65. The 52-week high for QIPT is $3.65, which means the stock is currently trading 0.0% from its annual peak. The 52-week low is $1.35, putting the stock 170.4% above its annual trough. Recent trading volume was 1.4M shares, reflecting moderate market activity.
Is QIPT Overvalued or Undervalued? — Valuation Analysis
Quipt Home Medical Corp. (QIPT) carries a value factor score of 39/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.44x, versus the sector average of 2.75x. The price-to-sales ratio is 0.63x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, QIPT trades at 21.38x EV/EBITDA, versus 6.34x for the sector.
At current multiples, Quipt Home Medical Corp. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
Quipt Home Medical Corp. Profitability — ROE, Margins, and Quality Score
Quipt Home Medical Corp. (QIPT) earns a quality factor score of 33/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -7.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -2.8% versus the sector average of -33.1%.
On a margin basis, Quipt Home Medical Corp. reports gross margins of 72.8%, compared to 71.5% for the sector. The operating margin is -0.7% (sector: -66.1%). Net profit margin stands at -3.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 32.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
QIPT Debt, Balance Sheet, and Financial Health
Quipt Home Medical Corp. has a debt-to-equity ratio of 74.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.04x, suggesting adequate working capital coverage. Total debt on the balance sheet is $84M.
QIPT has a beta of 0.34, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Quipt Home Medical Corp. is 53/100, reflecting average volatility within the normal range for its sector.
Quipt Home Medical Corp. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Quipt Home Medical Corp. reported revenue of $258M and earnings per share (EPS) of $-0.02. Net income for the quarter was $-8M. Gross margin was 72.8%. Operating income came in at $-1M.
In Q1 2026, Quipt Home Medical Corp. reported revenue of $81M and earnings per share (EPS) of $-0.02. Net income for the quarter was $-714,000. Gross margin was 71.9%. Revenue grew 32.0% year-over-year compared to Q1 2025. Operating income came in at $1M.
In FY 2025, Quipt Home Medical Corp. reported revenue of $245M and earnings per share (EPS) of $-0.24. Net income for the quarter was $-11M. Gross margin was 72.2%. Revenue grew -0.2% year-over-year compared to FY 2024. Operating income came in at $-4M.
In Q3 2025, Quipt Home Medical Corp. reported revenue of $58M and earnings per share (EPS) of $-0.07. Net income for the quarter was $-3M. Gross margin was 74.5%. Operating income came in at $-2M.
Over the past 8 quarters, Quipt Home Medical Corp. has demonstrated a growth trajectory, with revenue expanding from $246M to $258M. Investors analyzing QIPT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
QIPT Dividend Yield and Income Analysis
Quipt Home Medical Corp. (QIPT) does not currently pay a dividend. This is common among smaller companies in the Healthcare industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
QIPT Momentum and Technical Analysis Profile
Quipt Home Medical Corp. (QIPT) has a momentum factor score of 65/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 24/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 48/100 reflects moderate short selling activity.
QIPT vs Competitors — Healthcare Sector Ranking and Peer Comparison
Comparing QIPT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full QIPT vs S&P 500 (SPY) comparison to assess how Quipt Home Medical Corp. stacks up against the broader market across all factor dimensions.
QIPT Next Earnings Date
No upcoming earnings date has been announced for Quipt Home Medical Corp. (QIPT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy QIPT? — Investment Thesis Summary
Quipt Home Medical Corp. presents a balanced picture with arguments on both sides. The quality score of 33/100 flags below-average profitability. The value score of 39/100 indicates premium valuation. Price momentum is positive at 65/100, suggesting the trend favors buyers.
In summary, Quipt Home Medical Corp. (QIPT) earns a Hold rating with a composite score of 44.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on QIPT stock.
We'll email you when stocks you follow change their composite rating.
Institutional Research Dossier
Quipt Home Medical Corp. (QIPT) Deep Dive Analysis
Published on March 24, 2026
Action RatingHold
Sections
Executive Summary
Quipt Home Medical Corp. is currently rated a Hold, a reflection of its mixed financial performance and valuation. While the company demonstrates strong revenue growth and operates in a sector with favorable long-term trends, its persistent net losses, high debt levels, and elevated EV/EBITDA multiple raise concerns about its profitability and financial sustainability. The key takeaway is that Quipt's future hinges on its ability to translate revenue growth into consistent profitability and effectively manage its debt burden.
The company's aggressive acquisition strategy, while contributing to revenue growth, has also resulted in significant debt accumulation and integration challenges. The Hold rating acknowledges the potential upside from continued revenue expansion and improving operational efficiencies, but also recognizes the substantial risks associated with its current financial profile and competitive landscape. Investors should closely monitor Quipt's progress in achieving profitability and reducing its debt levels before considering a more bullish stance.
Business Strategy & Overview
Quipt Home Medical Corp. operates in the durable medical equipment (DME) and respiratory care sector, providing in-home medical equipment and supplies to patients with chronic conditions. The company's core business revolves around managing chronic disease states, focusing on patients with heart and pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. This involves providing equipment such as nebulizers, oxygen concentrators, CPAP and BiPAP units, and ventilator equipment, along with related supplies and services.
Quipt's revenue model is based on a combination of equipment sales, rentals, and recurring supply revenue. A significant portion of their revenue is derived from recurring rentals and resupply of consumables, which provides a degree of stability and predictability. The company's strategy involves expanding its geographic footprint through acquisitions and organic growth, aiming to increase its patient base and market share. They focus on acquiring smaller, regional DME providers to consolidate the fragmented market and achieve economies of scale.
The company's strategic positioning is centered on providing comprehensive in-home medical solutions, which allows them to capture a larger share of the patient's healthcare spending. By offering a wide range of products and services, Quipt aims to become a one-stop shop for patients with chronic conditions, improving patient outcomes and reducing healthcare costs. This integrated approach differentiates them from smaller, more specialized DME providers.
Quipt operates in a growing industry driven by an aging population, increasing prevalence of chronic diseases, and a shift towards home-based healthcare. The demand for DME and respiratory care is expected to continue to rise in the coming years, creating opportunities for Quipt to expand its business. However, the industry is also subject to regulatory changes and reimbursement pressures, which can impact profitability. The company must navigate these challenges effectively to maintain its competitive edge.
Execution Benchmarks audit
Revenue Growth
YOY expansion rate
32.0%
Sector: 10.6%
+200% VS SCTR
Economic Moat Analysis
Quipt Home Medical's economic moat is best characterized as Narrow. While the company benefits from certain industry dynamics, its competitive advantages are not strong enough to warrant a Wide moat rating. The DME industry, while fragmented, is also characterized by relatively low barriers to entry, limiting the potential for sustained outperformance.
One potential source of competitive advantage is switching costs. Patients with chronic conditions often rely on specific DME providers for their equipment and supplies, and switching to a new provider can be disruptive and inconvenient. This creates a degree of customer loyalty and reduces churn. However, these switching costs are not insurmountable, as patients can switch providers if they are dissatisfied with the service or if they find a better price.
Another potential source of competitive advantage is intangible assets, specifically the company's reputation and relationships with healthcare providers. A strong reputation for providing high-quality equipment and services can attract new patients and referrals. However, building a strong reputation takes time and effort, and it can be easily damaged by poor service or product quality. Furthermore, relationships with healthcare providers are important for generating referrals, but these relationships are not exclusive and can be cultivated by other DME providers as well.
Quipt's acquisition strategy aims to achieve efficient scale by consolidating smaller DME providers and achieving economies of scale. However, integrating acquired companies can be challenging, and there is no guarantee that Quipt will be able to realize the full potential of these acquisitions. Furthermore, the company faces competition from larger, more established DME providers with greater scale and resources.
Overall, Quipt's economic moat is limited by the relatively low barriers to entry in the DME industry and the lack of strong competitive advantages. While the company benefits from switching costs and intangible assets, these advantages are not strong enough to create a sustainable competitive advantage. The company's acquisition strategy aims to achieve efficient scale, but integration challenges and competition from larger players limit its potential.
Financial Health & Profitability
Quipt Home Medical's financial health presents a mixed picture. The company has demonstrated strong revenue growth, with a TTM revenue of $81.00 million and a revenue growth rate of 32.0% compared to the sector average of 10.7%. This growth is primarily driven by acquisitions and organic expansion. However, the company has struggled to translate this revenue growth into profitability.
The company's net income for the TTM period is $-714,000.00, and its net margin is -3.3%, compared to the sector average of -54.1%. While the company's net margin is better than the sector average, it is still negative, indicating that the company is not generating enough profit to cover its expenses. The company's EBITDA is $1.02 million, and its EV/EBITDA multiple is 60.1x, which is significantly higher than the sector average of 6.4x, suggesting that the company is overvalued relative to its earnings.
Quipt's balance sheet is highly leveraged, with a total debt of $84.00 million and a debt-to-equity ratio of 74.00, compared to the sector average of 30.00. This high level of debt increases the company's financial risk and limits its ability to invest in growth opportunities. The company's current ratio is 1.04, indicating that it has enough current assets to cover its current liabilities. However, the company's free cash flow is not available, making it difficult to assess its ability to generate cash from its operations.
Looking at the quarterly financial history, Quipt's revenue has generally been increasing, but its profitability has been inconsistent. The company's gross margin has been relatively stable, ranging from 71.1% to 74.5%. However, its operating margin has fluctuated, ranging from -3.1% to 1.3%. The company's net income has also been volatile, with periods of losses and periods of small profits. The company's free cash flow has been negative in several quarters, indicating that it is burning cash.
Overall, Quipt's financial health is weak. The company has demonstrated strong revenue growth, but it has struggled to translate this growth into profitability. The company's balance sheet is highly leveraged, and its free cash flow has been inconsistent. Investors should closely monitor the company's progress in improving its profitability and reducing its debt levels.
Valuation Assessment
Quipt Home Medical's valuation is challenging to assess due to its negative earnings and inconsistent cash flow generation. The company's P/E ratio is not applicable (N/A) because it is not currently profitable. Its EV/EBITDA multiple of 60.1x is significantly higher than the healthcare sector average of 6.4x, suggesting that the company is significantly overvalued based on its current earnings. This high multiple reflects investor expectations for future growth and profitability improvements, but also carries substantial risk.
Given the lack of positive free cash flow data, a traditional discounted cash flow (DCF) analysis is difficult to perform with confidence. The absence of this key metric makes it challenging to project future cash flows and determine a fair value for the company. Any DCF analysis would rely heavily on assumptions about future revenue growth, margin expansion, and capital expenditure requirements, which are subject to considerable uncertainty.
Relative valuation metrics, such as price-to-sales (P/S), are also less informative in this case due to the company's negative earnings and inconsistent profitability. While the company's revenue growth is strong, its inability to generate consistent profits raises concerns about the sustainability of its valuation. Investors are essentially paying a premium for future potential rather than current performance.
Considering the company's high debt levels and negative earnings, a conservative valuation approach is warranted. The current valuation appears to be pricing in significant improvements in profitability and cash flow generation, which may not materialize. The company's ability to execute its growth strategy and achieve economies of scale will be critical in justifying its current valuation.
Overall, Quipt Home Medical's valuation appears to be stretched, reflecting high expectations for future growth and profitability. The company's negative earnings, high debt levels, and inconsistent cash flow generation raise concerns about its ability to justify its current valuation. Investors should exercise caution and closely monitor the company's progress in improving its financial performance before considering a more bullish stance.
Risk & Uncertainty
Quipt Home Medical faces several specific, idiosyncratic risks that could negatively impact its business and financial performance. One of the most significant risks is regulatory and reimbursement pressures. The DME industry is subject to complex and evolving regulations, and changes in reimbursement policies by government and private payers could significantly reduce the company's revenue and profitability. For example, cuts in Medicare reimbursement rates for DME products could have a material adverse effect on Quipt's financial results.
Another key risk is integration risk associated with the company's acquisition strategy. Quipt has been actively acquiring smaller DME providers, and integrating these acquisitions can be challenging and time-consuming. Failure to successfully integrate acquired companies could result in lost revenue, increased expenses, and a decline in profitability. The company must effectively manage the integration process to realize the expected synergies and economies of scale.
Competition within the DME industry is also a significant risk. Quipt faces competition from larger, more established DME providers with greater scale and resources, as well as smaller, regional players. Increased competition could lead to price wars, reduced market share, and lower profitability. The company must differentiate itself through superior service, product quality, and customer relationships to maintain its competitive edge.
High debt levels pose another significant risk to Quipt's financial stability. The company's high debt-to-equity ratio increases its financial risk and limits its ability to invest in growth opportunities. Furthermore, the company's ability to service its debt obligations depends on its ability to generate sufficient cash flow. Failure to meet its debt obligations could result in default and bankruptcy.
Bulls Say / Bears Say
The Bull Case
BULL VIEWQuipt's aggressive acquisition strategy will continue to drive strong revenue growth and market share gains in the fragmented DME market.
BULL VIEWThe aging population and increasing prevalence of chronic diseases will fuel demand for Quipt's in-home medical equipment and services, leading to sustained revenue growth and improved profitability.
BULL VIEWSuccessful integration of acquired companies and realization of economies of scale will drive margin expansion and improved cash flow generation.
The Bear Case
BEAR VIEWQuipt's high debt levels and negative earnings make it vulnerable to economic downturns and changes in reimbursement policies.
BEAR VIEWIntegration challenges and increased competition will prevent Quipt from achieving its growth and profitability targets.
BEAR VIEWThe company's high EV/EBITDA multiple is unsustainable and reflects excessive optimism about its future prospects.
About the Author
Marques Blank
Founder & Chief Investment Officer, Blank Capital
Marques brings 15 years of institutional finance and investing experience, having overseen financial planning for a $1.6B defense business unit. He developed the proprietary 6-factor quantitative model used to score QIPT and 4,400+ other equities.
Quipt Home Medical Corp. exhibits a 15% valuation discount relative to institutional benchmarks. This represents a constructive entry window based on current multiples.
Return on Assets
Efficiency of asset utilization
-2.8%
Sector: -33.1%
Gross Margin
Pricing power and cost efficiency
72.8%
Sector: 71.5%
Operating Margin
Core business profitability
-0.7%
Sector: -66.1%
Net Margin
Bottom-line profitability
-3.3%
Sector: -58.7%
Factor Methodology
The Quality factor evaluates the persistence and magnitude of cash flows. Companies with scores >70 exhibit superior competitive moats and financial resilience through economic cycles.
